Sippican Capital Advisors Has $377,000 Stock Position in DaVita Inc. $DVA

Sippican Capital Advisors reduced its stake in DaVita Inc. (NYSE:DVA) by 66.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,322 shares of the company’s stock after selling 6,619 shares during the quarter. Sippican Capital Advisors’ holdings in DaVita were worth $377,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. NewEdge Advisors LLC lifted its stake in DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after buying an additional 88 shares during the period. Smartleaf Asset Management LLC lifted its stake in DaVita by 34.9% in the third quarter. Smartleaf Asset Management LLC now owns 452 shares of the company’s stock valued at $59,000 after buying an additional 117 shares during the period. Bank of Nova Scotia lifted its stake in DaVita by 2.5% in the third quarter. Bank of Nova Scotia now owns 4,933 shares of the company’s stock valued at $655,000 after buying an additional 120 shares during the period. TD Private Client Wealth LLC lifted its stake in DaVita by 30.9% in the third quarter. TD Private Client Wealth LLC now owns 564 shares of the company’s stock valued at $75,000 after buying an additional 133 shares during the period. Finally, Daiwa Securities Group Inc. lifted its stake in DaVita by 2.2% in the second quarter. Daiwa Securities Group Inc. now owns 6,502 shares of the company’s stock valued at $926,000 after buying an additional 138 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Trading Down 0.1%

Shares of DaVita stock opened at $149.89 on Monday. The company has a market capitalization of $10.01 billion, a P/E ratio of 15.13, a price-to-earnings-growth ratio of 0.52 and a beta of 0.92. The stock has a fifty day simple moving average of $148.90 and a 200 day simple moving average of $129.41. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $159.42.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.24 by $0.16. The firm had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The business’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on DVA. TD Cowen restated a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. UBS Group boosted their price objective on DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Barclays boosted their price objective on DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a report on Tuesday, February 3rd. Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Finally, Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $155.80.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.